A. Frost

发表

A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

Martin Büchert, Ulrike Fasol, Oliver Boix, 2012, Clinical Cancer Research.

PAC Fixed Dose: Pharmacokinetics of a 1-Hour Paclitaxel Infusion and Comparison to BSA-Normalized Drug Dosing

C. Unger, U. Massing, K. Mross, 2006, Oncology Research and Treatment.

Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours.

R. Kaiser, C. Unger, D. Trommeshauser, 2012, Current oncology.

Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis

R. Kaiser, M. Büchert, P. Stopfer, 2014, BMC Cancer.

DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study

J. Hennig, A. Ryan, M. Büchert, 2009, Journal of angiogenesis research.

Phase I study of BAY 57-9352, a VEGFR-2 inhibitor, in cycles of 14 days on/7 days off in patients with advanced solid tumors.

D. Strumberg, M. Scheulen, D. Voliotis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced refractory colorectal carcinoma (CRC).

M. Büchert, D. Strumberg, M. Scheulen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Anthracycline Extravasation with Dexrazoxane – Clinical Experience

C. Unger, K. Mross, A. Frost, 2006, Oncology Research and Treatment.

Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.

R. Kaiser, D. Trommeshauser, G. Munzert, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of two administration schedules of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumors.

R. Kaiser, D. Trommeshauser, G. Munzert, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

M Büchert, M Jeffers, M. Büchert, 2012, British Journal of Cancer.

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV

D. Strumberg, M. Scheulen, L. Edler, 2007, British Journal of Cancer.

Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors

R. Kaiser, C. Unger, Jürgen Henning, 2009, Clinical Cancer Research.

A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors

M. Scheulen, H. Richly, K. Mross, 2016, Cancer Chemotherapy and Pharmacology.

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours

D. Strumberg, M. Scheulen, P. Rajagopalan, 2008, British Journal of Cancer.

Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis.

M. Büchert, U. Fiedler, K. Mross, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A clinical phase I, pharmacokinetic (PK), and pharmacodynamic study of twice daily BIBF 1120 in advanced cancer patients

Jürgen Hennig, Ralph Strecker, J. Hennig, 2005 .

Phase II Study with 3rd- or 4th-Line Bendamustine (Flat Dose) Therapy in Patients with Metastatic Breast Cancer

C. Unger, K. Mross, A. Frost, 2009, Oncology Research and Treatment.

Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer

M. Büchert, D. Strumberg, M. Scheulen, 2011, Vascular cell.

A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors.

M. Scheulen, H. Richly, F. Fleischer, 2010 .

Metronomic Antiangiogenic Therapy with Capecitabine and Celecoxib in Advanced Tumor Patients – Results of a Phase II Study

Jürgen Hennig, Ralph Strecker, J. Hennig, 2007, Oncology Research and Treatment.

Phase I study of BAY 73–4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors: Final results of a dose-escalation study

C. Unger, D. Strumberg, M. Scheulen, 2008 .

Phase I study of BAY 73-4506, a multikinase inhibitor, administered for 21 days on/7 days off in patients with advanced solid tumors

M. Büchert, C. Unger, D. Voliotis, 2007 .

Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours.

C. Unger, D. Trommeshauser, G. Munzert, 2012, Current oncology.

A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumors.

M. Scheulen, H. Richly, K. Mross, 2010 .